Common use of EXPERTS Clause in Contracts

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The WithumSmith+Brown, PC, our independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 20232023 as set forth in their reports, filed which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our consolidated financial statements are incorporated by reference in reliance on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇WithumSmith+▇▇▇▇▇, LLCPC’s reports, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement on Form S-3 we filed with the SEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. Neither we nor any agent, underwriter or dealer has authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including our company. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content does not constitute a part of this prospectus and is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated Our financial statements as of, and for each of Sonoma Pharmaceuticalsthe years ended, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2017 and 2016 have been audited by ▇▇▇▇▇▇▇ so included in reliance on the report of Hoberman & ▇▇▇▇▇▇Lesser, LLCLLP, an independent registered public accounting firm, as set forth included in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report this prospectus given on the authority of such firm as experts in accounting auditing and auditingaccounting. We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the shares offered hereby. This prospectus supplement, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and our shares offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus supplement regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. We are a reporting company and file annual, quarterly and current reports, proxy statements and other information material with the SEC. You may read and copy our reports, proxy statements and other information, including the registration statement and any document we file with of which this prospectus supplement is a part at the Public Reference Room of the SEC, ▇▇▇ ▇ ▇▇▇▇▇▇, ▇. ▇., ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇. ▇. ▇▇▇▇▇. You may obtain information on the operation of the public reference rooms by calling the SEC at ▇-▇▇▇-▇▇▇-▇▇▇▇. The SEC also maintains a web site an Internet website that contains reports, proxy and information statements and other information regarding companiesabout issuers, such as ourslike us, that file documents electronically with the SEC. The address of the SEC’s website that site is ▇▇▇.▇▇▇.▇▇▇. The SEC allows us to "incorporate by reference" information on into this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC’s website . The information incorporated by reference is not deemed to be part of this prospectusprospectus supplement, and except for any references to information superseded by information in this website prospectus supplement or any other website are inactive textual references onlydocument that we file in the future with the SEC. This prospectus is part of a registration statement on Form S-3 supplement incorporates by reference the documents set forth below that we have previously filed with the SEC and all documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any portion of the respective filings that are furnished pursuant to register Item 2.02 or Item 7.01 of a Current Report on Form 8-K (including exhibits related thereto) or other applicable SEC rules, rather than filed) after the securities date of this prospectus supplement from their respective filing dates. These documents contain important information about us, our business and our finances. Annual Report on Form 10-K for the year ended December 31, 2017 April 2, 2018 Quarterly Report on Form 10-Q for the period ended March 31, 2018 May 15, 2018 Quarterly Report on Form 10-Q for the period ended June 30, 2018 August 14, 2018 Current Reports on Form 8-K January 18, 2018, May 24, 2018 and October 19, 2018 Schedule 14A Information Statement September 14, 2018 Description of Common Shares contained in our Registration Statement on Form 8-A January 25, 2017 At your request, either orally or in writing, we will provide you with a copy of any or all documents which are incorporated by reference. Such documents will be provided to be offered hereby. This prospectus does you free of charge, but will not contain all of the information included in the registration statementany exhibits, including certain unless those exhibits and schedulesare specifically incorporated by reference into those documents. You may obtain the registration statement and exhibits Requests should be addressed to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoingSachem Capital Corp., we maintain a website at ▇▇ ▇▇▇.▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇ ▇▇▇▇▇, attention: Chief Financial Officer, telephone number ( ▇▇▇) ▇▇▇-▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports . Sachem Capital Corp. may from time to time offer, in one or more series or classes, separately or together, and in amounts, at prices and on Form 10-Kterms to be set forth in one or more supplements to this prospectus, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments the following securities: • common shares, par value $0.001 per share; • preferred shares, par value $0.001 per share; • warrants to such document as soon as practicable after we electronically file such material with purchase common shares or furnish such documents to the SEC.preferred shares; • debt securities; or

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2018, as set forth in their report included thereinreport, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement of which this prospectus forms a part. Our financial statements are, and incorporated herein by reference. Such consolidated audited financial statements are to be included in subsequently filed documents will be, incorporated herein by reference in reliance upon on Ernst & Young LLP's reports pertaining to such report financial statements as of their respective dates, given on the their authority of such firm as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is supplement and the accompanying prospectus form part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered herebySEC. This prospectus does supplement and the accompanying prospectus do not contain all of the information included set forth in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and the exhibits to the registration statement from or the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it documents incorporated by reference into herein and therein. For further information with respect to us and the securities that we are offering under this prospectusprospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement and the documents incorporated by reference herein and therein. You should rely only on the information contained in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies have not authorized anyone else to provide you with different information. We are not making an offer of our Annual Reports these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on Form 10-Kthe front page of this prospectus supplement, Quarterly Reports on Form 10-Q regardless of the time of delivery of this prospectus supplement or any sale of the securities offered hereby. We file annual, quarterly and Current Reports on Form 8-K other reports, proxy and any amendments to such document as soon as practicable after we electronically file such material information statements and other information with or furnish such documents to the SEC.Securities and Exchange

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.this prospectus by reference from the Company’s annual report Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2018 have been audited by ▇▇▇▇▇▇▇ Deloitte & ▇▇▇▇▇▇, LLCTouche LLP, an independent registered public accounting firm, as set forth stated in their report included thereinreport, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with public over the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of Internet at the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The Copies of certain information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a are also available on our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor not a part of this prospectus and is it not incorporated by reference into in this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q consolidated subsidiaries and Current Reports on Form 8-K and the securities we are offering. Statements in this prospectus concerning any amendments to such document we filed as soon as practicable after we electronically file such material with or furnish such documents an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC’s website.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 20232022, as set forth in their report, which is incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Such financial statements are, and audited financial statements to be included in subsequently filed on June 21documents will be, 2023, have been audited by ▇▇incorporated herein in reliance upon the reports of ▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing. The financial statements as of and for the year ended December 31, LLC2021 incorporated herein by reference from the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as set forth stated in their report included thereinreport, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with public over the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of Internet at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The Copies of certain information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a are also available on our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither not a part of this prospectus supplement and information contained on, or that can be relied upon for investment purposes nor accessed through, our website is it not incorporated by reference into in this prospectusprospectus supplement. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies This prospectus supplement and the accompanying prospectus are part of a registration statement we filed with the SEC. This prospectus supplement and the accompanying prospectus omit some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q consolidated subsidiary and Current Reports on Form 8-K the securities we are offering. Statements in this prospectus supplement and the accompanying prospectus concerning any amendments to such document we filed as soon as practicable after we electronically file such material with or furnish such documents an exhibit to the SECregistration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements.

EXPERTS. The financial statements of the Registrant as of and for the year ended December 30, 2023, incorporated by reference in this prospectus, have been audited by Hudgens, LLC, an independent registered public accounting firm, as stated in its report incorporated by reference herein, and have been incorporated in reliance upon the authority of such firm as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K the Registrant as of and for the year ended March December 31, 20232022, filed on June 21, 2023incorporated by reference in this prospectus, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm, as set forth stated in their report included therein, and incorporated herein by referencereport. Such consolidated financial statements are incorporated herein by reference herein, and have been incorporated in reliance upon such report the firm given on the their authority of such firm as experts in accounting and auditing. This report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This Prospectus Supplement constitutes a part of the Registration Statement. As permitted by the SEC’s rules, this Prospectus Supplement and the Base Prospectus, which form a part of the Registration Statement, do not contain all the information that is included in the Registration Statement and its exhibits. You will find additional information about us in the Registration Statement and its exhibits. Any statements made in this Prospectus Supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the Registration Statement or otherwise filed by us with the SEC for a more complete understanding of such documents or matter. We file annual, quarterly quarterly, and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at no cost from the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s Our corporate website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our The information on our corporate website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into in this prospectus. We make available at ▇▇▇Prospectus Supplement, the Base Prospectus, or any other prospectus supplement that we file, and you should not consider it a part of this Prospectus Supplement, the Base Prospectus or any other such prospectus supplement.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements as of Sonoma PharmaceuticalsDecember 31, Inc. appearing in Sonoma Pharmaceuticals2019 and 2018, Inc.’s annual report on Form 10-K and for the year ended March 31years then ended, 2023, filed on June 21, 2023, incorporated by reference in this prospectus and the registration statement have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇so incorporated in reliance on the report of BDO USA, LLCLLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report , given on the authority of such said firm as experts in accounting auditing and auditingaccounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The Additional information on the SEC’s website about Heat Biologics, Inc. is not part of this prospectuscontained at our website, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information on our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of on our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document website our SEC filings as soon as reasonably practicable after we electronically file such material those reports are filed with or furnish such documents to the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 20232020, filed on June 21July 10, 20232020, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCMarcum LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticalsthis prospectus by reference from Xenetic Biosciences, Inc.’s annual report and subsidiaries’ Annual Report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023as amended, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCMarcum LLP, an independent registered public accounting firm, as set forth stated in their report included thereinreport, and which are incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. We file annualhave filed a registration statement, quarterly and current reportsof which this prospectus is a part, proxy statements and other covering the securities offered hereby. As allowed by SEC rules, this prospectus does not contain all of the information with the SEC. You may read and copy set forth in the registration statement and any document we file with the exhibits thereto. We refer you to the registration statement and the exhibits thereto for further information. This prospectus is qualified in its entirety by such other information. Copies of the registration statement, including the exhibits and schedules to the registration statement, may be examined without charge at the public reference room of the SEC, ▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇., ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇. The Information about the operation of the public reference room may be obtained by calling the SEC at 1-800- SEC-0330. Copies of all or a portion of the registration statement can be obtained from the public reference room of the SEC upon payment of prescribed fees. Our SEC filings, including our registration statement, are also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of available to you on the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The We file reports, proxy statements and other information with the SEC as required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Those reports, proxy statements and other information are available for inspection and copying at the Public Reference Room and on the SEC’s website is not part of this prospectus, and any references referred to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at on the Internet with the address ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated We are not incorporating by reference into this prospectus the information on our website, and you should not consider our website to be a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements and management’s assessment of Sonoma Pharmaceuticals, Inc. appearing the effectiveness of internal control over financial reporting (which is included in Sonoma Pharmaceuticals, Inc.Management’s annual report Report On Internal Control Over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2023 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCso incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company’s requirement for additional financing to fund future operations as described in Note 3 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we have on file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a an effective “shelf” registration statement on Form S-3 that we filed with the SEC relating to register the securities to that may be offered herebyand sold hereunder. This prospectus does not contain all The full registration statement, including exhibits thereto, contains additional relevant information about us and these securities that, as permitted by the rules and regulations of the information SEC, we have not included in this prospectus supplement or the accompanying prospectus. You should read the full registration statement for further information about us and these securities. Any statement made in this prospectus supplement or the accompanying prospectus concerning the contents of any contract, agreement or other document is only a summary of the actual contract, agreement or other document. If we have filed any contract, agreement or other document as an exhibit to the registration statement, including certain exhibits and schedulesthen you should read the exhibit for a more complete understanding of the document or matter involved. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our We make our SEC filings available on our website, free of charge, as soon as reasonably practicable after such materials are filed with, or furnished to, the SEC. Information presented or accessed through our website content is not incorporated into, or made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into a part of, this prospectus supplement or the accompanying prospectus. We make Our SEC filings are available from the SEC’s Internet site at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇, which contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. In addition, our common stock is listed on The Nasdaq Global Select Market and similar information concerning us can be inspected and copied at the offices of The Nasdaq Stock Market, One Liberty Plaza, ▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsBlackSky Technology Inc., Inc. appearing incorporated by reference in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023this prospectus, have been audited by ▇▇▇▇▇▇▇ Deloitte & ▇▇▇▇▇▇, LLCTouche LLP, an independent registered public accounting firm, as set forth stated in their report included therein, and incorporated herein by referencereport. Such consolidated financial statements are incorporated herein by reference in reliance upon such the report given on the authority of such firm firm, given their authority as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s an Internet website is ▇▇▇▇▇.▇▇▇.▇▇▇. The ▇ that contains reports, proxy and information on statements, and other information about issuers, like us, that file electronically with the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We also maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available available, free of charge, on our investor relations website at ▇▇▇▇▇://▇▇.▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇▇ copies of / our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Q, Current Reports on Form 8-K and any amendments to such document these reports as soon as reasonably practicable after we electronically file such material with filing or furnish such documents furnishing those reports to the SEC. Information contained on our website is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses in this prospectus is an inactive textual reference only. This prospectus and any prospectus supplement is part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities that we are offering. Forms of any indenture or other documents establishing the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under cover of a Current Report on Form 8-K and incorporated in this prospectus by reference. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should read the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC’s website, as provided above.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2022, as set forth in their report included thereinreport, which is incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s report, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The ▇ that contains reports, proxy and information on statements, and other information regarding issuers, such as us, that file electronically with the SEC’s website is not part . Copies of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we certain information filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a are also available on our website at ▇▇▇.▇://▇▇▇▇▇▇.▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content does not constitute a part of this prospectus and is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into in this prospectus. We make available at ▇▇▇have included our website address as an inactive textual reference only.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The OUM & Co. LLP, our independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm, 2020 as set forth in their report included thereinreports, which are incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such Our consolidated financial statements are incorporated herein by reference in reliance upon such report on OUM & Co. LLP’s reports, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including our company. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.’s annual report this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2019 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCso incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company’s requirement for additional financing to fund future operations as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. This prospectus supplement and the accompanying prospectus are part of a registration statement we filed with the SEC. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus supplement and the accompanying prospectus or incorporated by reference herein or therein. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectus supplement. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC. , including Surface Oncology, Inc. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇. We have included our website address in this prospectus supplement solely as an inactive textual reference.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The audited consolidated financial statements and management’s assessment of Sonoma Pharmaceuticalsthe effectiveness of internal control over financial reporting of Sun Communities, Inc. appearing incorporated by reference in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for this prospectus and elsewhere in the year ended March 31, 2023, filed on June 21, 2023, registration statement of which this prospectus is a part have been audited so incorporated by reference in reliance upon the reports of ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇LLP, LLC, an independent registered public accounting firmaccountants, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting and auditing. We are subject to the informational requirements of the Exchange Act, and, in accordance therewith, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web an Internet site that contains reports, proxy and information statements statements, and other information regarding companies, such as ours, issuers that file documents electronically with the SEC. The address of the SEC’s website that site is ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoingAdditionally, we maintain a make these filings available, free of charge, through the “Investors & Media” section of our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as reasonably practicable after we electronically file such material with materials with, or furnish such documents them to, the SEC. The information on the website listed above, except as described in the section titled “Incorporation of Certain Documents by Reference” below, is not, and should not be, considered part of this prospectus and is not incorporated by reference into this document. We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities offered in connection with this prospectus. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information regarding us and the securities, please refer to the registration statement and the documents filed or incorporated by reference as exhibits to the registration statement. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete and, in each instance, you should refer to the copy of such contract or document filed as an exhibit to or incorporated by reference in the registration statement. Each statement as to the contents of such contract or document is qualified in all respects by such reference. You may obtain copies of the registration statement and its exhibits from the SEC as indicated above or from us.

EXPERTS. The consolidated audited financial statements of Sonoma PharmaceuticalsOragenics, Inc. appearing as of December 31, 2018 and 2017, and for the two-year period ended December 31, 2018, included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 20232018, filed on June 21, 2023, incorporated by reference in this prospectus have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC▇ ▇▇▇▇▇▇ P.C., an independent registered public accounting firm, as set forth stated in their report included thereindated March 29, 2019, which is incorporated by reference herein, and has been so incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The Copies of certain information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s are also available on our website listed above. In addition to the foregoing, we maintain a website at ▇▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies Information contained in or accessible through our website does not constitute a part of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q this prospectus and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SECis not incorporated by reference in this prospectus.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.’s annual report this prospectus by reference to the Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2018 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCso incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company’s requirement for additional financing to fund future operations as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC. , including Surface Oncology, Inc. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇. Information contained in or accessible through our website does not constitute a part of this prospectus.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2022, as set forth in their report included therein(which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s report, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website ▇▇▇▇▇.▇▇▇.▇▇▇ that contains reports, proxy and information statements and other information regarding companiesregistrants. Our SEC filings, such as oursincluding our registration statement and the exhibits and schedules thereto, that file documents electronically with are available on the SEC. The address of the SEC’s SEC website is at ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 20232021, filed on June 21July 14, 20232021, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCMarcum LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsRocket Lab USA, Inc. appearing incorporated by reference in Sonoma Pharmaceuticalsthis Prospectus, and the effectiveness of Rocket Lab USA, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, internal control over financial reporting have been audited by ▇▇▇▇▇▇▇ Deloitte & ▇▇▇▇▇▇, LLCTouche LLP, an independent registered public accounting firm, as set forth stated in their report included therein, and incorporated herein by referencereports. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority reports of such firm firm, given their authority as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web an Internet site that contains reports, proxy and information statements statements, and other information regarding companies, such as ours, that file documents electronically with us. Our SEC filings are available to the SEC. The address of public over the Internet at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The Copies of certain information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a are also available on our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content and the information contained or connected to our website is made available for informational purposes only. It should neither be relied upon for investment purposes nor not a part of this prospectus or any prospectus supplement and is it not incorporated by reference into in this prospectusprospectus or any prospectus supplement. We make available at ▇▇▇.This prospectus is part of a registration statement on Form S-3 we filed with the SEC under the Securities Act with respect to the securities offered by this prospectus and the applicable prospectus supplement. This prospectus and the applicable prospectus supplement do not contain all of the information set forth in the registration statement and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus and the applicable prospectus supplement, you should read the registration statement of which this prospectus is a part, including its exhibits and schedules. Statements contained in this prospectus and the applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC’s ▇▇▇▇▇▇▇▇▇▇▇▇▇ database or our website.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2020, as set forth in their report included therein(which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 1 to the consolidated financial statements), which is incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s report, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website ▇▇▇▇▇.▇▇▇.▇▇▇ that contains reports, proxy and information statements and other information regarding companiesregistrants. Our SEC filings, such as oursincluding our registration statement and the exhibits and schedules thereto, that file documents electronically with are available on the SEC. The address of the SEC’s SEC website is at ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.this prospectus by reference from the Company’s annual report Annual Report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ Deloitte & ▇▇▇▇▇▇, LLCTouche LLP, an independent registered public accounting firm, as set forth stated in their report included thereinreport, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including Fulgent. The address of the SEC’s SEC website is ▇w ▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at w ▇▇.▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.’s annual report this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2023 have been audited by so incorporated in reliance on the report of ▇▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇▇, LLCCertified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. This prospectus supplement constitutes a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC’s rules, this prospectus supplement and accompanying prospectus, which form a part of the registration statement, do not contain all the information that is included in the registration statement. You will find additional information about us in the registration statement. Any statements made in this prospectus supplement or accompanying prospectus concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter. We are subject to the informational requirements of the Exchange Act, and, in accordance with those requirements, file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read Such reports, proxy statements and copy the other information, as well as this registration statement and any document we file with the SEC. The exhibits and schedules thereto, are available on the SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The information Copies of these documents may also be accessed on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a our website at http:// ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our internet website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it and the information contained therein or connected thereto are not incorporated by reference into this prospectus. We make available at ▇▇▇prospectus or any amendment or supplement thereto.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K 10‑K for the year ended March December 31, 20232016 as set forth in their report, filed which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on June 21Ernst & Young LLP’s report, 2023given on their authority as experts in accounting and auditing. The financial statements for the year ended December 31, 2014 incorporated in this Prospectus by reference to the Annual Report on Form 10‑K for the year ended December 31, 2014 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCso incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company’s ability to continue as a going concern as described in Note 2 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. This prospectus is part of a registration statement we filed with the Securities and Exchange Commission, or SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and statement, as well as any other document we file filed by us with the SEC, at the SEC’s Public Reference Room at ▇▇▇ ▇ ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC‑0330. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including us. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsFlex Pharma, Inc. appearing in Sonoma PharmaceuticalsFlex Pharma, Inc.’s annual report on Annual Report (Form 10-K K) for the year ended March December 31, 2023, filed on June 21, 20232018, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇Young LLP, LLC, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and statement, as well as any other document we file filed by us with the SEC, at the SEC’s Public Reference Room at ▇▇▇ ▇ ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including Flex. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇-▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March Data Storage Corporation as of December 31, 20232023 and 2022 and for each of the two years in the period ended December 31, filed on June 21, 2023, 2023 incorporated by reference in this prospectus and in the registration statement of which this prospectus forms a part have been audited by so incorporated in reliance on the report of ▇▇▇▇▇▇▇▇▇ & ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, LLCP.A., an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The information Our SEC filings are also available on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at our website,▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our ▇ under the heading “SEC Filings.” The reference to our website content is made available for informational purposes an inactive textual reference only. It should neither , the information contained in, and that can be relied upon for investment purposes nor accessed through our website, is it not incorporated by reference into and is not a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of on our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document website our SEC filings as soon as reasonably practicable after we electronically file such material those reports are filed with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.’s annual report this Prospectus by reference to the Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, 2021 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLCso incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to, among other securities, the shares of common stock offered by this prospectus supplement and accompanying prospectus. This prospectus supplement and the accompanying prospectus do not contain all of the information included in the registration statement. For further information pertaining to us and our common stock we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and its exhibits. Statements contained in this prospectus supplement and the accompanying prospectus concerning any of our contracts, agreements or other documents are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, we refer you to the copy of the contract or document that has been filed. Each statement in this prospectus supplement and the accompanying prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. We are subject to the informational requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements reports and other information with the SEC. You may read and copy the registration statement and any document we file Our filings with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with are available to the SEC. The address of public on the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information on You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with or furnished to the SEC’s website is not part of this prospectus, and any references to this website or any other website . Those filings are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits also available to the registration statement from the SEC at the address listed above public on, or from the SEC’s website listed above. In addition to the foregoingaccessible through, we maintain a our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement and accompanying prospectus.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements as of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, 2021 and 2020 and for the years then ended incorporated by reference in this prospectus and in the Registration Statement have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇so incorporated in reliance on the report of BDO USA, LLCLLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report , given on the authority of such said firm as experts in accounting auditing and auditingaccounting. The report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. We are subject to the reporting requirements of the Exchange Act, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains these reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of at the SEC’s website is public reference facilities at ▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇., ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at ▇-▇▇▇-▇▇▇-▇▇▇▇ for more information about the operation of the public reference facilities. SEC filings are also available at the SEC’s web site at ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is only part of a registration statement on Form S-3 that we have filed with the SEC under the Securities Act and therefore omits certain information contained in the registration statement. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus, and you should refer to register the securities applicable exhibit or schedule for a complete description of any statement referring to be offered herebyany contract or other document. This prospectus does not contain all You may inspect a copy of the information included in the registration statement, including certain the exhibits and schedules. You may , without charge, at the public reference room or obtain the registration statement and exhibits to the registration statement a copy from the SEC at upon payment of the address listed above or from fees prescribed by the SEC’s website listed above. In addition to the foregoing, we We also maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇, through which you can access our SEC filings. Our The website content addresses referenced herein are not intended to function as hyperlinks, and the information contained in our website, the SEC’s website or any other website referenced herein is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsAnnexon, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March as of December 31, 20232023 and 2022, filed on June 21and for each of the years in the two-year period ended December 31, 2023, have been audited incorporated by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇reference herein and in the registration statement in reliance upon the report of KPMG LLP, LLC, an independent registered public accounting firm, as set forth in their report included thereinincorporated by reference herein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with public over the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of internet at the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our The information contained in, or that can be accessed through, our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into not part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇Life Sciences, LLCInc. as of December 31, an 2019 and 2018, and for each of the years in the three-year period ended December 31, 2019, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, as set forth in their report included thereinincorporated by reference herein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting and auditing. The audit report covering the December 31, 2019 consolidated financial statements refers to a change in the method of accounting for leases as of January 1, 2019 due to the adoption of FASB Accounting Standards Update 2016-02, Leases (Topic 842). This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and statement, as well as any other document we file filed by us with the SEC, at the SEC’s Public Reference Room at ▇▇▇ ▇ ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including ▇▇▇▇▇. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.this prospectus by reference from the Company’s annual report Annual Report on Form 10-K for the year ended dated March 314, 2023, filed on June 21, 2023, 2020 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC▇ ▇▇▇▇▇▇ P.C., an independent registered public accounting firm, as set forth stated in their report included therein, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditingauditing ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ P.C. has no interest in the shares being registered in this filing. We are a public company and file annual, quarterly and current reports, proxy statements and other information with the SECSecurities and Exchange Commission (“SEC”).You can request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may read and copy Our SEC filings are also available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at the SEC’s website is web site at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The In addition, we maintain a web site that contains information on regarding our company, including copies of reports, proxy statements and other information we file with the SEC’s . The address of our web site is ▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇. Except for the documents specifically incorporated by reference into this prospectus, information contained on our website is or that can be accessed through our website does not constitute a part of this prospectus, and any references to this . We have included our website or any other website are address only as an inactive textual references onlyreference and do not intend it to be an active link to our website. This prospectus is supplement and the accompanying prospectus are part of a registration statement on Form S-3 that we filed with the SEC to register registering the securities to that may be offered herebyand sold hereunder. This prospectus does not contain all of the information included in the The registration statement, including certain exhibits thereto, contains additional relevant information about us and schedulesthese securities that, as permitted by the rules and regulations of the SEC, we have not included in this prospectus supplement or the accompanying prospectus. You may obtain A copy of the registration statement and exhibits to can be obtained at the address set forth above. You should read the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇for further information about us and these securities.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report ourAnnual Report on Form 10-K for the year ended March December 31, 20232017, filed on June 21and the effectiveness of our internal control over financial reporting as of December 31, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2017, as set forth in their report included thereinreports, which are incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP's reports, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on information contained in this prospectus or incorporated by reference into this prospectus. We have not authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with at the SEC's public reference room at ▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇., ▇▇▇▇▇▇▇▇▇▇, ▇.▇., ▇▇▇▇▇. The address of Please call the SEC’s website is SEC at ▇.▇▇▇.▇▇▇.▇▇▇. The ▇ for further information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all operation of the information included in the registration statement, including certain exhibits and schedulespublic reference room. You may obtain the registration statement and exhibits Our SEC filings are also available to the registration statement from the SEC public at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a 's website at ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated audited financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated by reference in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for this prospectus and elsewhere in the year ended March 31, 2023, filed on June 21, 2023, registration statement have been audited so incorporated by ▇reference in reliance on the report of ▇▇▇▇▇▇ & ▇▇▇▇▇▇LLP, LLC, an independent registered public accounting firmaccountants, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting and auditing. We file annualhave filed with the SEC a registration statement on Form S-3 under the Securities Act relating to securities offered by this prospectus. This prospectus, quarterly which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits thereto. For more information regarding us and current reportsthe securities offered by this prospectus, proxy statements we refer you to the full registration statement, including the exhibits filed therewith. This prospectus summarizes certain provisions of certain contracts and other documents filed as exhibits to which we refer you. Because the summaries may not contain all of the information with that you may find important, you should review the SECfull text of those documents. You may read and copy the access our SEC filings, including this registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reportsstatement, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The We are subject to the information on reporting requirements of the Exchange Act and file reports, proxy statements, and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC’s website is not part of this prospectus, and any references referred to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We also maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available , at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies which you may access these materials free of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document charge as soon as reasonably practicable after we they are electronically file such material with filed with, or furnish such documents to furnished to, the SEC. Information contained on, or that can be accessed through, our website does not constitute part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsBird Global, Inc. Inc., appearing in Sonoma PharmaceuticalsBird Global, Inc.’s annual report on 's Annual Report (Form 10-K K) for the year ended March December 31, 2023, filed on June 21, 2023, 2022 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇ LLP, LLC, an predecessor independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial statements), included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus, or incorporated by reference in this prospectus. We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available to the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of public at the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The Copies of certain information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed by us with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s are also available on our website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇▇.▇▇. Our The information contained on, or accessible through, our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into this prospectus. We make available at ▇▇▇, and you should not consider any information contained in, or that can be accessed through, our website as part of this prospectus, or in deciding whether to purchase our securities.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2022, as set forth in their report included thereinreport, which is incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s report, given on the their authority of such firm as experts in accounting and auditing. We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the securities offered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement, of which it is a part, and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC’s website at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. We are subject to the information and periodic reporting requirements of the Exchange Act, and we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file documents with the SEC. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companiesissuers, such as oursincluding us, that file documents electronically with the SEC. The address of You may obtain documents that we file with the SEC’s website is SEC at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. The information We also make these documents available on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a our website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇.com. Our website content and the information contained or accessible through our website is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not incorporated by reference into in this prospectus. We make available at ▇▇▇, and you should not consider it part of this prospectus.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing incorporated in Sonoma Pharmaceuticals, Inc.this prospectus by reference from the Company’s annual report Annual Report on Form 10-K for the year ended March 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ Deloitte & ▇▇▇▇▇▇, LLCTouche LLP, an independent registered public accounting firm, as set forth stated in their report included thereinreport, and which is incorporated herein by reference. Such consolidated financial statements are have been so incorporated herein by reference in reliance upon such the report given on the authority of such firm given upon their authority as experts in accounting and auditing. This prospectus is part of a registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference therein. For further information with respect to us and the common stock we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the common stock offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of at the SEC’s website is public reference room at ▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇., ▇▇▇▇▇▇▇▇▇▇, ▇.▇., ▇▇▇▇▇. Please call the SEC at ▇.▇▇▇.▇▇▇.▇▇▇. The ▇ for further information on the operation of the public reference room. Our SEC filings are also available to the public at the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated ‌ Ernst & Young LLP, independent registered public accounting firm, has audited our financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 2023, filed on June 21, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2017, as set forth in their report included thereinreport, which is incorporated by reference in this prospectus and incorporated herein by referenceelsewhere in the registration statement. Such consolidated Our financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s report, given on the their authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and statement, as well as any other document we file filed by us with the SEC, at the SEC’s Public Reference Room at ▇▇▇ ▇ ▇▇▇▇▇▇ ▇▇, ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC also maintains a web site website that contains reports, proxy and information statements and other information regarding companies, such as ours, issuers that file documents electronically with the SEC, including Tocagen. The address of the SEC’s SEC website is ▇▇▇.▇▇▇.▇▇▇. The information on the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we We maintain a website at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our Information contained in or accessible through our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into does not constitute a part of this prospectus. We make available at ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements of Sonoma Pharmaceuticals, Inc. appearing included in Sonoma Pharmaceuticals, Inc.’s annual report our Annual Report on Form 10-K for the year ended March December 31, 20232021, filed on June 21and the effectiveness of our internal control over financial reporting as of December 31, 2023, have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇, LLC, an independent registered public accounting firm2021, as set forth in their report included thereinreports, which are incorporated by reference in this prospectus supplement and incorporated herein by referenceelsewhere in this registration statement. Such Our consolidated financial statements are incorporated herein by reference in reliance upon such report on Ernst & Young LLP’s reports, given on the their authority of such firm as experts in accounting and auditing. We have filed a registration statement on Form S-3 with the SEC under the Securities Act. This prospectus supplement and the accompanying prospectus are part of the registration statement but the registration statement includes and incorporates by reference additional information and exhibits. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of that site on the SEC’s website worldwide web is ▇▇▇.▇▇▇.▇▇▇. The SEC permits us to “incorporate by reference” the information on contained in documents we file with the SEC’s website , which means that we can disclose important information to you by referring you to those documents rather than by including them in this prospectus supplement and the accompanying prospectus. Information that is not incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus and you should read it with the same care that you read this prospectus supplement and the accompanying prospectus. Later information that we file with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference, in this prospectus supplement and the accompanying prospectus, and any references will be considered to this website or any other website are inactive textual references only. This prospectus is be a part of a registration statement on Form S-3 that we this prospectus supplement and the accompanying prospectus from the date those documents are filed. We have filed with the SEC, and incorporate by reference in this prospectus supplement and the accompanying prospectus: ∎ our Annual Report on Form 10-K for the year ended December 31, 2021; and ∎ the description of our common stock set forth in Exhibit 4.2 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. We also incorporate by reference all additional documents that we file with the SEC to register under the securities to be offered hereby. This prospectus does not contain all terms of Section 13(a), 13(c), 14 or 15(d) of the information included in Exchange Act that are made after the initial filing date of the registration statement of which this prospectus supplement and the accompanying prospectus is a part and the effectiveness of the registration statement, including certain exhibits as well as between the date of this prospectus supplement and schedulesthe termination of any offering of securities offered by this prospectus supplement and the accompanying prospectus. We are not, however, incorporating, in each case, any documents or information that we are deemed to furnish and not file in accordance with SEC rules. You may obtain request a copy of any or all of the registration statement documents incorporated by reference but not delivered with this prospectus supplement and exhibits to the registration statement from the SEC accompanying prospectus, at no cost, by writing or telephoning us at the following address listed above or from the SEC’s website listed above. In addition to the foregoingand number: Investor Relations, we maintain a website at Invitae Corporation, ▇▇▇.▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇., ▇▇▇▇▇▇▇▇▇▇ ▇▇▇.▇▇ and (▇▇▇ copies of our Annual Reports on Form 10▇) ▇▇▇-K▇▇▇▇. We will not, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments however, send exhibits to such document as soon as practicable after we electronically file such material with or furnish such documents to those documents, unless the SECexhibits are specifically incorporated by reference in those documents.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsNuZee, Inc. appearing as of September 30, 2021 and 2020 and for each of the two years in Sonoma Pharmaceuticalsthe period ended September 30, Inc.’s annual report 2021, incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for the year ended March 31September 30, 2023, filed on June 21, 2023, 2021 have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇so incorporated in reliance on the report of MaloneBailey, LLCLLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such said firm as experts in accounting auditing and auditingaccounting. We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the common stock offered by this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus are part of that registration statement, but do not contain all of the information included in the registration statement or the exhibits. For further information about us, we refer you to the registration statement and to its exhibits and schedules. You may obtain the full registration statement and exhibits from the SEC or from us, as provided below. We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy Our SEC filings are available over the registration statement and any document we file with the SEC. The SEC also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of Internet at the SEC’s website is at ▇▇▇.▇▇▇.▇▇▇. The SEC maintains a website that contains reports, proxy and information on the SEC’s website is not part of this prospectus, statements and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 information regarding issuers that we filed file electronically with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇. Our website address is ▇▇▇.▇▇▇▇▇▇▇.▇▇▇. Our The information contained on, or that can be accessed through, our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it not a part of this prospectus supplement or the accompanying prospectus or incorporated by reference into this prospectus supplement or the accompanying prospectus, and you should not consider information on our website to be part of this prospectus supplement or the accompanying prospectus. We make available at ▇▇▇have included our website address as an inactive textual reference only.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC.

EXPERTS. The consolidated financial statements of Sonoma PharmaceuticalsMoleculin Biotech, Inc. appearing in Sonoma Pharmaceuticalsas of December 31, Inc.’s annual report on Form 10-K 2015 and for the year ended March period from July 28, 2015 (inception) to December 31, 2023, filed on June 21, 2023, 2015 incorporated by reference in this prospectus have been audited by ▇▇▇▇▇▇▇ & ▇▇▇▇▇▇GBH CPAs, LLCPC, an independent registered public accounting firm, as set forth stated in their report included appearing therein, and incorporated herein by reference. Such consolidated financial statements are have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. The audited financial statements of Moleculin Biotech, Inc. as of December 31, 2016 and for the year then ended incorporated herein by reference in this prospectus and elsewhere in the registration statement have been incorporated by reference in reliance upon such the report given on of ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ LLP, independent registered public accountants, upon the authority of such said firm as experts in accounting and auditing. We This prospectus supplement and the accompanying prospectus are part of a registration statement on Form S-3 we filed with the SEC under the Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement or the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy the registration statement and any document we file information filed by us with the SEC at the SEC’s public reference section, ▇▇▇ ▇ ▇▇▇▇▇▇, ▇.▇., ▇▇▇▇▇▇▇▇▇▇, ▇.▇. ▇▇▇▇▇. Information regarding the operation of the public reference section can be obtained by calling ▇-▇▇▇-▇▇▇-▇▇▇▇. The SEC also maintains a web an Internet site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the SEC. The address of the SEC’s website is at ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇▇ that contains reports, statements and other information about issuers, such as us, who file electronically with the SEC. The SEC allows us to “incorporate by reference” into this prospectus supplement the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information on the SEC’s website incorporated by reference is not considered to be a part of this prospectusprospectus supplement, and information in documents that we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus supplement. We incorporate by reference in this prospectus supplement the documents listed below and any references future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of the offering under this website prospectus supplement; provided, however, that we are not incorporating, in each case, any documents or any other website are inactive textual references only. This prospectus is part of a registration statement information deemed to have been furnished and not filed in accordance with SEC rules: • Our Annual Report on Form S-3 that we 10-K for the year ended December 31, 2016 (filed on April 3, 2017); • Our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2017 (filed on May 12, 2017) and June 30, 2017 (filed on August 11, 2017); • Our Current Reports on Form 8-K filed on February 9, 2017; February 23, 2017; March 14, 2017; March 22, 2017; April 17, 2017; May 19, 2017; May 31, 2017; June 27, 2017; June 30, 2017; July 12, 2017; July 27, 2017; August 25, 2017; and September 15, 2017; • Definitive Proxy Statement on Schedule 14A relating to the Company’s 2017 Annual Meeting of Stockholders (filed on April 28, 2017); and • the description of our common stock, par value $0.001 per share contained in our Registration Statement on Form 8-A, dated and filed with the SEC on April 28, 2016, and any amendment or report filed with the SEC for the purpose of updating the description. All reports and other documents we subsequently file pursuant to register Section 13(a), 13(c), 14 or 15(d) of the securities Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of this prospectus supplement and accompanying prospectus, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and deemed to be offered hereby. This part of this prospectus does not contain all supplement from the date of the information included in the registration statement, including certain exhibits filing of such reports and schedulesdocuments. You may obtain a copy of any or all of the registration statement and exhibits documents referred to the registration statement from the SEC above, which may have been or may be incorporated by reference into this prospectus supplement, including exhibits, at no cost to you by writing or telephoning us at the address listed above or from the SEC’s website listed above. In addition to the foregoingfollowing address: Attention: Corporate Secretary, we maintain a website at ▇▇▇.▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇.▇ ▇▇▇. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at ▇▇▇., ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇., telephone (▇▇▇ copies of our Annual Reports on Form 10▇) ▇▇▇-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as practicable after we electronically file such material with or furnish such documents to the SEC▇▇▇▇.